Evaluation of the Expression of CD-4 and CD-45 Count among Patients Having Non-Small Cell Lung Cancer

Abstract

Lung cancer is one of the most lethal types of cancer in case of both men and women. It has a higher mortality rate than the three most widespread malignancies (colon, breast, and pancreas combined).The demographic makeup of lung cancer has evolved during the last few years. The majority of reports, however, have limitations due to their small sample sizes, brief follow-up periods, and uneven patterns. There hasn't been a thorough analysis of long-term tendencies that change throughout time. The clinical importance of CD-4 and CD-45 expression in patients with non-small cell lung cancer was investigated using tissue microarrays created from the biopsies of 50 patients with non-small cell lung cancer.Immunohistochemistry was performed to identify the expression of CD-4 and CD-45 in a tissue microarray (IHC).Patients' overall survival (OS) was tracked through telephone contact. For statistical analysis, BIM SPSS statistics 22 and GraphPad primes 8 were both employed.The expression of CD-4 and CD-45 in the same patients was significantly positively correlated by immunohistochemical staining (Person correlation=0.4, P<0.0001). According to Kaplan-Meier survival analysis, CD-4high patients had better survival than CD-4low patients;Compared to CD-4lowCD-45low patients, CD-4highCD-45high individuals had a greater OS.The expression of CD-4 and CD-45 in tumor tissue was positively connected with OS and showed a favorable association with CD-4 and CD-45 in non-small cell lung cancer.